Onyx Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
EMERYVILLE, Calif., Feb. 2 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the 12th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2010 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). Interested parties may access a live webcast of the presentation on our website at:
It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through February 23, 2010.
About Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing NexavarŽ (sorafenib) tablets a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors, and ONX 0801, a targeted alpha-folate inhibitor, currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.
NexavarŽ (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.
SOURCE Onyx Pharmaceuticals, Inc.
You May Also Like